论文部分内容阅读
作者采用双盲随机分组对照方法,应用大剂量病毒唑静脉滴注治疗流行性出血热(简称出血热)早期患者,观察其对各病期心电图变化的影响。结果表明:(1)出血热患者各病期普遍存在心电图异常;(2)早期应用大剂量病毒唑治疗,能够减轻出血热患者的心脏损害,降低心电图异常改变率;(3)病毒唑组每例平均用20.02克病毒唑治疗,其心电图异常改变率无一项显著高于安慰剂组,说明病毒唑对心脏无明显毒副作用。作者还对早期应用大剂量病毒唑治疗出血热减轻心脏损害的机理进行了探讨。
The authors used a double-blind, randomized, group-controlled trial of high-dose intravenous injection of ribavirin to treat early-stage patients with epidemic hemorrhagic fever (hemorrhagic fever) and to examine their effects on changes in electrocardiograms during each phase. The results showed that: (1) electrocardiogram abnormalities were common in all stages of hemorrhagic fever patients; (2) early application of high-dose ribavirin treatment could reduce the cardiac damage and reduce the rate of abnormal ECG changes; (3) Cases with an average of 20.02 grams of ribavirin treatment, ECG abnormalities, none of them was significantly higher than the placebo group, indicating that ribavirin no obvious side effects on the heart. The author also discussed the mechanism of early application of high-dose ribavirin to treat hemorrhagic fever and reduce heart damage.